
Beppino C. Giovanella, Ph.D.
Laboratory Director
Zhisong Cao, Ph.D.
Associate Laboratory Director, Chief Chemist
Dana Vardeman
Laboratory Supervisor
Constantine Markides, Ph.D.
Chief Pharmacologist
Doug Coil
Deputy Laboratory Supervisor
Xing (Lucy) Liu, Ph.D.
Research Scientist, Analytical Chemistry
Anthony (Tony) Kozielski
Section Supervisor, Chemotherapy
Yang Wang, Ph.D.
Research Scientist, Synthetic Chemistry
John Mendoza
Tissue Culture Supervisor
Edward (Eddie) Petry, Jr.
Vivarium Section Supervisor
Lauren Battershell
Research Technician
Linh Luong
Research Technician
Joanna de la Cruz
Research Technician
Albert DeJesus
Research Technician
Gabriel Rodriguez
Research Technician
The cancer drug bexarotene quickly eliminates Alzheimer's disease-associated amyloid beta from the brain and reverses memory problems in mice, a new study finds. The results suggest that bexarotene could help the 5.4 million Americans with Alzheimer's disease.
An international research team has made a breakthrough that could change the way pediatric cancers are treated in the future. The researchers identified two genetic mutations responsible for up to 40 per cent of glioblastomas in children.
“I have been constantly impressed not only with the CHRISTUS Stehlin Foundation’s rich legacy of transformative research, but also the tenacious commitment of foundation staff to the vision of Dr. Stehlin. A connection between this vision and the mission of our sponsoring congregations was immediately clear, as both seek not only to treat illness, but also honor the dignity inherent in every person.”
Tom Royer, M.D.,
CEO Emeritus, CHRISTUS Health, 2011